Copyright
©The Author(s) 2022.
World J Clin Oncol. Aug 24, 2022; 13(8): 688-701
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.688
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.688
Figure 1 Flow chart of eligible patients included in the analysis according to the diagnosis of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma on explant pathology (January 1998-July 2019, southern Brazil).
LT: Liver transplant; HCC: Hepatocellular carcinoma; HCC-CC: Hepatocellular cholangiocarcinoma; ICC: Intrahepatic cholangiocarcinoma.
Figure 2 Post-liver transplant 3-year risk of recurrence, overall mortality, and recurrence-free survival in patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma compared with patients with hepatocellular carcinoma, matched 1:8 for pretransplant tumor characteristics (Pre liver transplant characteristics) and pathologic tumor characteristics (Post liver transplant characteristics).
aPre liver transplant (LT) characteristics: serum alpha-fetoprotein and radiologic tumor diameter; bPost LT characteristics: Tumor diameter, grade/differentiation, microvascular invasion. PSM: Propensity score matching; LT: Liver transplant; HCC: Hepatocellular carcinoma; HCC-CC: Hepatocellular cholangiocarcinoma; ICC: Intrahepatic cholangiocarcinoma.
Figure 3 Kaplan-Meier curves representing.
A: post-liver transplant overall survival; B: recurrence-free survival in patients with intrahepatic cholangiocarcinoma compared with patients with hepatocellular carcinoma, matched 1:8 for pretransplant tumor characteristics; C: post-liver transplant overall survival; D: recurrence-free survival in patients with intrahepatic cholangiocarcinoma compared with patients with hepatocellular carcinoma matched 1:8 for posttransplant tumor characteristics. CIs: Confidence intervals; HCC: hepatocellular carcinoma; HRs: Hazard ratios; ICC: intrahepatic cholangiocarcinoma.
Figure 4 Kaplan-Meier curves representing.
A: post-liver transplant overall survival; B: recurrence-free survival in patients with mixed hepatocellular-cholangiocarcinoma compared with patients with hepatocellular carcinoma (HCC), matched 1:8 for pretransplant tumor characteristics; C: post-liver transplant overall survival; D: recurrence-free survival in patients with mixed hepatocellular-cholangiocarcinoma compared with patients with hepatocellular carcinoma matched 1:8 for posttransplant tumor characteristics. HCC: hepatocellular carcinoma; HCC-CC: hepatocellular-cholangiocarcinoma; HRs: Hazard ratios; CIs: Confidence intervals.
- Citation: Brandão ABM, Rodriguez S, Fleck Jr AM, Marroni CA, Wagner MB, Hörbe A, Fernandes MV, Cerski CT, Coral GP. Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant. World J Clin Oncol 2022; 13(8): 688-701
- URL: https://www.wjgnet.com/2218-4333/full/v13/i8/688.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i8.688